You B - Search Results

1

Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy.

Bylicki O, Gan HK, Joly F, Maillet D, You B, Péron J. Bylicki O, et al. Among authors: you b. Ann Oncol. 2015 Jan;26(1):231-237. doi: 10.1093/annonc/mdu489. Epub 2014 Oct 29. Ann Oncol. 2015. PMID: 25355720 Free article.

2

Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review.

You B, Gan HK, Pond G, Chen EX. You B, et al. J Clin Oncol. 2012 Jan 10;30(2):210-6. doi: 10.1200/JCO.2011.37.0890. Epub 2011 Dec 12. J Clin Oncol. 2012. PMID: 22162583 Review.

3

Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.

Gan HK, You B, Pond GR, Chen EX. Gan HK, et al. Among authors: you b. J Natl Cancer Inst. 2012 Apr 18;104(8):590-8. doi: 10.1093/jnci/djs141. Epub 2012 Apr 6. J Natl Cancer Inst. 2012. PMID: 22491345 Review.

4

Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review.

Péron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B. Péron J, et al. Among authors: you b. J Natl Cancer Inst. 2012 Jul 3;104(13):982-9. doi: 10.1093/jnci/djs259. Epub 2012 Jul 3. J Natl Cancer Inst. 2012. PMID: 22761273 Review.

5

[Consistency in the analysis and reporting of PEPs in oncology randomized controlled trials from registration to publication: a systematic review].

Boespflug A, Gan H, Chen EX, Pond G, You B. Boespflug A, et al. Among authors: you b. Bull Cancer. 2012 Oct;99(10):943-52. doi: 10.1684/bdc.2012.1651. Bull Cancer. 2012. PMID: 23034429 Review. French.

6

Influence of statistician involvement on reporting of randomized clinical trials in medical oncology.

Péron J, You B, Gan HK, Maillet D, Chen EX, Pond GR. Péron J, et al. Among authors: you b. Anticancer Drugs. 2013 Mar;24(3):306-9. doi: 10.1097/CAD.0b013e32835c3561. Anticancer Drugs. 2013. PMID: 23221738

7

Response.

Péron J, You B. Péron J, et al. Among authors: you b. J Natl Cancer Inst. 2013 Feb 6;105(3):244-5. doi: 10.1093/jnci/djs511. J Natl Cancer Inst. 2013. PMID: 23520607 No abstract available.

8

Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.

Péron J, Maillet D, Gan HK, Chen EX, You B. Péron J, et al. Among authors: you b. J Clin Oncol. 2013 Nov 1;31(31):3957-63. doi: 10.1200/JCO.2013.49.3981. Epub 2013 Sep 23. J Clin Oncol. 2013. PMID: 24062406 Review.

9

A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment.

Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M, Colomban O, You B. Almufti R, et al. Among authors: you b. Ann Oncol. 2014 Jan;25(1):41-56. doi: 10.1093/annonc/mdt382. Ann Oncol. 2014. PMID: 24356619 Free article. Review.

10

The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.

Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J. Maillet D, et al. Among authors: you b. Ann Oncol. 2016 Jan;27(1):192-8. doi: 10.1093/annonc/mdv485. Epub 2015 Oct 19. Ann Oncol. 2016. PMID: 26483049 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,023 results

Search Page

Filters